<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns:mv="http://macVmlSchemaUri" xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta name=Title content="">
<meta name=Keywords content="">
<meta http-equiv=Content-Type content="text/html; charset=macintosh">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 14">
<meta name=Originator content="Microsoft Word 14">
<link rel=File-List
href="Rules%20Document%20for%20Heart%20Failure%202013_v13_files/filelist.xml">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Oshiro, Connie M.</o:Author>
  <o:LastAuthor>Samson Tu</o:LastAuthor>
  <o:Revision>6</o:Revision>
  <o:TotalTime>16</o:TotalTime>
  <o:Created>2014-01-17T00:58:00Z</o:Created>
  <o:LastSaved>2014-01-22T21:11:00Z</o:LastSaved>
  <o:Pages>10</o:Pages>
  <o:Words>3600</o:Words>
  <o:Characters>20524</o:Characters>
  <o:Company>Veteran Affairs</o:Company>
  <o:Lines>171</o:Lines>
  <o:Paragraphs>48</o:Paragraphs>
  <o:CharactersWithSpaces>24076</o:CharactersWithSpaces>
  <o:Version>14.0</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData
href="Rules%20Document%20for%20Heart%20Failure%202013_v13_files/themedata.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:HideSpellingErrors/>
  <w:HideGrammaticalErrors/>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>JA</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
  DefSemiHidden="true" DefQFormat="false" DefPriority="99"
  LatentStyleCount="276">
  <w:LsdException Locked="false" Priority="0" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>
  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" Priority="10" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" Priority="11" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" Priority="22" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" Priority="59" SemiHidden="false"
   UnhideWhenUsed="false" Name="Table Grid"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]--><![if !supportAnnotations]>
<style id="dynCom" type="text/css"><!-- --></style>
<script language="JavaScript"><!--
function msoCommentShow(anchor_id, com_id)
{
	if(msoBrowserCheck()) 
		{
		c = document.all(com_id);
		if (null != c)
			{
			a = document.all(anchor_id);
			var cw = c.offsetWidth;
			var ch = c.offsetHeight;
			var aw = a.offsetWidth;
			var ah = a.offsetHeight;
			var x  = a.offsetLeft;
			var y  = a.offsetTop;
			var el = a;
			while (el.tagName != "BODY") 
				{
				el = el.offsetParent;
				x = x + el.offsetLeft;
				y = y + el.offsetTop;
				}
			var bw = document.body.clientWidth;
			var bh = document.body.clientHeight;
			var bsl = document.body.scrollLeft;
			var bst = document.body.scrollTop;
			if (x + cw + ah / 2 > bw + bsl && x + aw - ah / 2 - cw >= bsl ) 
				{ c.style.left = x + aw - ah / 2 - cw; }
			else 
				{ c.style.left = x + ah / 2; }
			if (y + ch + ah / 2 > bh + bst && y + ah / 2 - ch >= bst ) 
				{ c.style.top = y + ah / 2 - ch; }
			else 
				{ c.style.top = y + ah / 2; }
			c.style.visibility = "visible";
}	}	}
function msoCommentHide(com_id) 
{
	if(msoBrowserCheck())
		{
		c = document.all(com_id);
		if (null != c)
		{
		c.style.visibility = "hidden";
		c.style.left = -1000;
		c.style.top = -1000;
		} } 
}
function msoBrowserCheck()
{
	ms = navigator.appVersion.indexOf("MSIE");
	vers = navigator.appVersion.substring(ms + 5, ms + 6);
	ie4 = (ms > 0) && (parseInt(vers) >= 4);
	return ie4;
}
if (msoBrowserCheck())
{
	document.styleSheets.dynCom.addRule(".msocomanchor","background: infobackground");
	document.styleSheets.dynCom.addRule(".msocomoff","display: none");
	document.styleSheets.dynCom.addRule(".msocomtxt","visibility: hidden");
	document.styleSheets.dynCom.addRule(".msocomtxt","position: absolute");
	document.styleSheets.dynCom.addRule(".msocomtxt","top: -1000");
	document.styleSheets.dynCom.addRule(".msocomtxt","left: -1000");
	document.styleSheets.dynCom.addRule(".msocomtxt","width: 33%");
	document.styleSheets.dynCom.addRule(".msocomtxt","background: infobackground");
	document.styleSheets.dynCom.addRule(".msocomtxt","color: infotext");
	document.styleSheets.dynCom.addRule(".msocomtxt","border-top: 1pt solid threedlightshadow");
	document.styleSheets.dynCom.addRule(".msocomtxt","border-right: 2pt solid threedshadow");
	document.styleSheets.dynCom.addRule(".msocomtxt","border-bottom: 2pt solid threedshadow");
	document.styleSheets.dynCom.addRule(".msocomtxt","border-left: 1pt solid threedlightshadow");
	document.styleSheets.dynCom.addRule(".msocomtxt","padding: 3pt 3pt 3pt 3pt");
}
// --></script>
<![endif]>
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:Arial;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"Courier New";
	panose-1:2 7 3 9 2 2 5 2 4 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"\FF2D\FF33 \660E\671D";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:"\FF2D\FF33 \660E\671D";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:128;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:fixed;
	mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:-520082689 -1073717157 41 0 66047 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Comment Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.25in right 6.5in;
	font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 3.25in right 6.5in;
	font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-noshow:yes;
	mso-style-priority:35;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	color:#4F81BD;
	mso-themecolor:accent1;
	font-weight:bold;}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:blue;
	mso-themecolor:hyperlink;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:purple;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"Comment Text";
	mso-style-link:"Comment Subject Char";
	mso-style-next:"Comment Text";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:Tahoma;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-noshow:yes;
	mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	mso-add-space:auto;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Comment Text";
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Header;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Footer;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"Comment Text Char";
	mso-style-link:"Comment Subject";
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Balloon Text";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;
	font-family:Tahoma;
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-size:11.0pt;
	mso-ansi-font-size:11.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
 /* Page Definitions */
@page
	{mso-footnote-separator:url(":Rules Document for Heart Failure 2013_v13_files:header.htm") fs;
	mso-footnote-continuation-separator:url(":Rules Document for Heart Failure 2013_v13_files:header.htm") fcs;
	mso-endnote-separator:url(":Rules Document for Heart Failure 2013_v13_files:header.htm") es;
	mso-endnote-continuation-separator:url(":Rules Document for Heart Failure 2013_v13_files:header.htm") ecs;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 31.5pt 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
@list l0
	{mso-list-id:16270850;
	mso-list-type:hybrid;
	mso-list-template-ids:-1918067250 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1
	{mso-list-id:130364838;
	mso-list-type:hybrid;
	mso-list-template-ids:-1018296676 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l2
	{mso-list-id:182788021;
	mso-list-type:hybrid;
	mso-list-template-ids:1290333042 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l2:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l2:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l2:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l2:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l2:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l2:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l2:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l2:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l2:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.75in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l3
	{mso-list-id:459497979;
	mso-list-type:hybrid;
	mso-list-template-ids:1408272588 1838433776 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l3:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.0in;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l3:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.5in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l3:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.0in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l3:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.5in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l3:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l3:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.5in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l3:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.0in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l3:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.5in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l3:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:5.0in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l4
	{mso-list-id:473371246;
	mso-list-type:hybrid;
	mso-list-template-ids:-1808077406 67698693 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l4:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l4:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l4:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l4:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l4:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l4:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l4:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.75in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l4:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:5.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l5
	{mso-list-id:516621491;
	mso-list-type:hybrid;
	mso-list-template-ids:398199714 67698689 1838433776 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l5:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l5:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l5:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l5:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l5:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l5:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l5:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l5:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l6
	{mso-list-id:634221805;
	mso-list-type:hybrid;
	mso-list-template-ids:39330092 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l6:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l6:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l6:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l6:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l6:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l6:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l6:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l6:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l7
	{mso-list-id:641227576;
	mso-list-type:hybrid;
	mso-list-template-ids:-1973360380 -517298136 -1255743384 1908193266 1562292748 116429970 601151216 1260190462 2046094784 -2102863298;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l7:level2
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l7:level3
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l7:level4
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l7:level5
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:2.25in;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l7:level6
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:2.75in;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l7:level7
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:3.25in;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l7:level8
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:3.75in;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l7:level9
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:4.25in;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l8
	{mso-list-id:680932579;
	mso-list-type:hybrid;
	mso-list-template-ids:1744314932 1838433776 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l8:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l8:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l8:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l8:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l8:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l8:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l8:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l8:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l8:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l9
	{mso-list-id:949505555;
	mso-list-type:hybrid;
	mso-list-template-ids:-544676230 1841969272 -1374758306 126231124 2002020130 -435126894 -314164278 194431480 -695834878 280929126;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l9:level2
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l9:level3
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l9:level4
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l9:level5
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:2.25in;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l9:level6
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:2.75in;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l9:level7
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:3.25in;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l9:level8
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:3.75in;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l9:level9
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:4.25in;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l10
	{mso-list-id:1066958233;
	mso-list-type:hybrid;
	mso-list-template-ids:-1604798926 1838433776 1838433776 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l10:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l10:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l10:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l10:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l10:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l10:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l10:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l10:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l10:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l11
	{mso-list-id:1128470872;
	mso-list-type:hybrid;
	mso-list-template-ids:-1798670136 1838433776 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l11:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.0in;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l11:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.5in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.0in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l11:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.5in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l11:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.5in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l11:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.0in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l11:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.5in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:5.0in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l12
	{mso-list-id:1166047275;
	mso-list-type:hybrid;
	mso-list-template-ids:1339355206 1838433776 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l12:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.0in;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l12:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.5in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l12:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.0in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l12:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.5in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l12:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l12:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.5in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l12:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.0in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l12:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.5in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l12:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:5.0in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l13
	{mso-list-id:1378043388;
	mso-list-type:hybrid;
	mso-list-template-ids:370340574 1838433776 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l13:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l13:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l13:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l13:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l13:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l13:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l13:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l13:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l13:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l14
	{mso-list-id:1602177617;
	mso-list-type:hybrid;
	mso-list-template-ids:1871109580 1838433776 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l14:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l14:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l14:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l14:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l14:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l14:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l14:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l14:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l14:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l15
	{mso-list-id:1623729240;
	mso-list-type:hybrid;
	mso-list-template-ids:260590770 11822996 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l15:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-font-weight:bold;}
@list l15:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l15:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l15:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l15:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l15:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l15:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l15:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l15:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.75in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l16
	{mso-list-id:1636567887;
	mso-list-type:hybrid;
	mso-list-template-ids:1401424160 67698689 1838433776 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l16:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l16:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l16:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l16:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l16:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l16:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l16:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l16:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l16:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l17
	{mso-list-id:1637950000;
	mso-list-type:hybrid;
	mso-list-template-ids:-1928405688 -1508580862 663761308 -1773134076 1666455074 -1962085394 -2037479636 380380796 -465269822 947670552;}
@list l17:level1
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l17:level2
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:.75in;
	mso-level-number-position:left;
	margin-left:.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l17:level3
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:1.25in;
	mso-level-number-position:left;
	margin-left:1.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l17:level4
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:1.75in;
	mso-level-number-position:left;
	margin-left:1.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l17:level5
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:2.25in;
	mso-level-number-position:left;
	margin-left:2.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l17:level6
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:2.75in;
	mso-level-number-position:left;
	margin-left:2.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l17:level7
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:3.25in;
	mso-level-number-position:left;
	margin-left:3.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l17:level8
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:3.75in;
	mso-level-number-position:left;
	margin-left:3.75in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l17:level9
	{mso-level-number-format:bullet;
	mso-level-text:¥;
	mso-level-tab-stop:4.25in;
	mso-level-number-position:left;
	margin-left:4.25in;
	text-indent:-.25in;
	font-family:Arial;
	mso-bidi-font-family:"Times New Roman";}
@list l18
	{mso-list-id:1952735429;
	mso-list-type:hybrid;
	mso-list-template-ids:1072565864 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l18:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.0in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l18:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:1.5in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l18:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.0in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l18:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:2.5in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l18:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.0in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l18:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:3.5in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l18:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.0in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l18:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:4.5in;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l18:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:5.0in;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l19
	{mso-list-id:2075394179;
	mso-list-type:hybrid;
	mso-list-template-ids:-2092682804 1838433776 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l19:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l19:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l19:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l19:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l19:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l19:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l19:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l19:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l19:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l20
	{mso-list-id:2119831174;
	mso-list-type:hybrid;
	mso-list-template-ids:587891914 1838433776 1838433776 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l20:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l20:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Calibri;
	mso-fareast-font-family:Cambria;
	mso-fareast-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;}
@list l20:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l20:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l20:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l20:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l20:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l20:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l20:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Cambria;
	mso-ascii-font-family:Cambria;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Cambria;
	mso-hansi-theme-font:minor-latin;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1027"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:.5in'>

<div class=WordSection1>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:18.0pt;line-height:115%'>Rules Document for Heart Failure 2013<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'>Eligibility <o:p></o:p></span></u></b></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l1 level1 lfo2'><![if !supportLists]><span
style='font-size:12.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>á<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
115%'>Presence of heart failure (ICD9 Codes &#8211; See Appendix A) AND<o:p></o:p></span></b></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l1 level1 lfo2'><![if !supportLists]><span
style='font-size:12.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>á<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;line-height:
115%'>Absence of heart transplant (ICD9 Codes &#8211; See Appendix A)<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;line-height:115%'>Note about eligibility
- </span></b><span style='font-size:12.0pt;line-height:115%'>If values for the following
variables are missing, all recommendations will be suppressed: <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l15 level1 lfo4'><![if !supportLists]><span
style='font-size:12.0pt;line-height:115%;font-family:Calibri;mso-fareast-font-family:
Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='font-size:12.0pt;line-height:115%'>Left ventricular ejection fraction <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l15 level1 lfo4'><![if !supportLists]><span
style='font-size:12.0pt;line-height:115%;font-family:Calibri;mso-fareast-font-family:
Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='font-size:12.0pt;line-height:115%'>Sex<o:p></o:p></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l15 level1 lfo4'><![if !supportLists]><span
style='font-size:12.0pt;line-height:115%;font-family:Calibri;mso-fareast-font-family:
Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='font-size:12.0pt;line-height:115%'>Systolic blood pressure <o:p></o:p></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l15 level1 lfo4'><![if !supportLists]><span
style='font-size:12.0pt;line-height:115%;font-family:Calibri;mso-fareast-font-family:
Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
style='font-size:12.0pt;line-height:115%'>Creatinine <o:p></o:p></span></p>

<p class=MsoNormal style='margin-left:21.75pt'><a style='mso-comment-reference:
ST_1;mso-comment-date:20140122T1253'><span style='font-size:12.0pt;line-height:
115%'>There are additional</span></a><span class=MsoCommentReference><span
style='font-size:9.0pt;line-height:115%'><![if !supportAnnotations]><a
class=msocomanchor id="_anchor_1"
onmouseover="msoCommentShow('_anchor_1','_com_1')"
onmouseout="msoCommentHide('_com_1')" href="#_msocom_1" language=JavaScript
name="_msoanchor_1">[ST1]</a><![endif]><span style='mso-special-character:comment'>&nbsp;</span></span></span><span
style='font-size:12.0pt;line-height:115%'> missing values that will suppress
recommendations only for certain drugs, and these are noted below. <o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'>Goals<o:p></o:p></span></u></b></p>

<p class=MsoListParagraph style='text-indent:-.25in;mso-list:l6 level1 lfo6'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>There are no specific goals for HF patients,
unlike other CDS programs such as Glycemic Control.</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'>Behavior of the CDS</span></u></b><u><span
style='font-size:12.0pt;line-height:115%'><o:p></o:p></span></u></p>

<p class=MsoNormal><span style='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Compelling
Indications</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l18 level1 lfo8'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Absence <span class=GramE>of<span
style="mso-spacerun:yes">&nbsp; </span>therapy</span> then recommend therapy</p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l18 level1 lfo8'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence <span class=GramE>of<span
style="mso-spacerun:yes">&nbsp; </span>therapy</span> then no action</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.5in'>Absolute Contraindications
(absolute contraindication behavior trumps compelling indication behavior)</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l18 level1 lfo8'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Absence <span class=GramE>of<span
style="mso-spacerun:yes">&nbsp; </span>therapy</span> then do not recommend to
start<span style="mso-spacerun:yes">&nbsp; </span>therapy </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;mso-add-space:
auto;text-indent:-.25in;mso-list:l18 level1 lfo8'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence <span class=GramE>of<span
style="mso-spacerun:yes">&nbsp; </span>therapy</span> then recommend to stop
therapy</p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Relative
Contraindications</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l18 level1 lfo8'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Absence <span class=GramE>of<span
style="mso-spacerun:yes">&nbsp; </span>therapy</span> then recommend therapy
(with a cautionary message)</p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l18 level1 lfo8'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence <span class=GramE>of<span
style="mso-spacerun:yes">&nbsp; </span>therapy</span> then cautionary alert </p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><a href="#ACEAbsoluteContraindications">There are,</a>
however, <b style='mso-bidi-font-weight:normal'>special cases</b> (e.g. do not
add, but do not remove if condition X exists) for some recommendations, and
these are noted below. </p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>There are also certain <b style='mso-bidi-font-weight:normal'>messages</b>
that we would like to test, which are noted below as well. </p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:14.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'>ACE Inhibitors<o:p></o:p></span></u></b></p>

<p class=MsoNormal><a name=ACECompellingIndication><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'><o:p><span
 style='text-decoration:none'>&nbsp;</span></o:p></span></u></b></a></p>

<span style='mso-bookmark:ACECompellingIndication'></span>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'>Guideline:</span></u>
ÔACE inhibitors</b> are recommended in patients with <span class=SpellE>HF<i>r</i>EF</span>
and current or prior symptoms, unless contraindicated, to reduce morbidity and
mortality (343, 412-414). (<i>Level of Evidence: A</i>)Õ &#8211; <span
class=SpellE>Yancy</span> 7.3.2.2 <span class=SpellE><span class=GramE>pg</span></span>
49</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Compelling
indication:<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l8 level1 lfo10'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=<span class=GramE>40<span
style="mso-spacerun:yes">&nbsp; </span>AND</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l8 level1 lfo10'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent SBP&gt;=110 AND</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l8 level1 lfo10'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Creatinine &lt;2.5 (male) OR creatinine&lt;2.3
(female) </p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.25in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><a name=ACEAbsoluteContraindications><b style='mso-bidi-font-weight:
normal'>Absolute contraindications<o:p></o:p></b></a></p>

<span style='mso-bookmark:ACEAbsoluteContraindications'></span>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Angioedema as a past recorded reaction to ACE
inhibitor OR</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent K&gt;5 </p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.25in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>Note: while Pregnancy should be a strong contraindication,
there is no way to determine pregnancy from the data we have, so we will
instead issue a message to all women of childbearing age. </p>

<p class=MsoListParagraph style='margin-left:1.25in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Relative
contraindications<o:p></o:p></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Aortic stenosis OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Hypertrophic cardiomyopathy OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Renal artery <span class=GramE>stenosis<span
style="mso-spacerun:yes">&nbsp; </span>OR</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Chronic kidney disease (CKD) stage3 or 4 OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>30 &lt;<span class=SpellE>eGFR</span>&lt;60 OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Active prescription for <span class=SpellE>Aliskiren</span>
OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Active prescription for Potassium-sparing
diuretics</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Special cases:<span
style="mso-spacerun:yes">&nbsp; </span><o:p></o:p></b></p>

<p class=MsoNormal>Case 1) If patient has a prescription for an ACE inhibitor,
do not stop prescription if:</p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent SBP&lt;110 OR </p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Creatinine &gt;=2.5 (male) OR creatinine&gt;=2.3
(female) OR</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style="mso-spacerun:yes">&nbsp;</span><span
class=SpellE><span class=GramE>eGFR</span></span> &lt;=30 (not yet encoded) OR</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Angioedema as a past recorded reaction to ARB
(not yet encoded)</p>

<p class=MsoNormal style='margin-left:.75in'><a
href="#ACEAbsoluteContraindications"><span class=SpellE>ACEAbsoluteContraindications</span></a></p>

<p class=MsoNormal>Case 2) If patient does not have a prescription for an ACE
inhibitor, DO NOT recommend ACE inhibitor if:</p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent SBP&lt;110 OR</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Creatinine &gt;=2.5 (male) OR creatinine&gt;=2.3
(female) OR</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span style="mso-spacerun:yes">&nbsp;</span><span
class=SpellE><span class=GramE>eGFR</span></span> &lt;=30 (not yet encoded) OR</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Angioedema as a past recorded reaction to ARB (not
yet encoded)</p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>Future Case 3) <span class=GramE>Any</span> increase of more
than 20% in creatinine AFTER prescription for an <span class=SpellE>ACEi</span>/ARB.&nbsp;
The comparison is FROM the baseline creatinine prior to initiation of <span
class=SpellE>ACEi</span>/ARB (the most recent creatinine prior to first <span
class=SpellE>ACEi</span>/ARB) TO the peak creatinine within 3 months after
initiation of <span class=SpellE>ACEi</span>/ARB. <b style='mso-bidi-font-weight:
normal'>NOTE:</b> we are not currently capturing the data necessary to evaluate
this criterion, so we will revisit this when we have the data. </p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'>Angiotensin Receptor Blockers (ARB)</span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'>Guideline:</span></u>
ARBs </b>are recommended in patients with <span class=SpellE>HFrEF</span> with
current or prior symptoms<b><i> </i></b>who are ACE inhibitor intolerant,
unless contraindicated, to reduce morbidity and mortality (108, 345, 415, 450).
(<i>Level of <span class=SpellE>Evidence<span class=GramE>:A</span></span></i>)
&#8211; <span class=SpellE>Yancy</span> 7.3.2.3 <span class=SpellE>pg</span> 51</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><a name=ARBCompellingIndication><b style='mso-bidi-font-weight:
normal'>Compelling indication<o:p></o:p></b></a></p>

<span style='mso-bookmark:ARBCompellingIndication'></span>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=<span class=GramE>40<span
style="mso-spacerun:yes">&nbsp; </span>AND</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(Adverse reaction to ACE inhibitor AND not on
ACE inhibitor) AND</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent SBP&gt;=110 AND</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Creatinine &lt;2.5 (male) OR creatinine&lt;2.3
(female) AND</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Absolute
contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Angioedema as a past recorded reaction to ARB OR</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent K&gt;5 </p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Relative
contraindications<o:p></o:p></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Aortic stenosis OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Hypertrophic cardiomyopathy OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Renal artery <span class=GramE>stenosis<span
style="mso-spacerun:yes">&nbsp; </span>OR</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Chronic kidney disease (CKD) stage3 or 4 or 30
&lt;<span class=SpellE>eGFR</span>&lt;60 OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>20% increase in creatinine after initiation of <span
class=SpellE>ACEi</span> or ARB OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=SpellE>Aliskiren</span> OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Potassium-sparing diuretics</p>

<p class=MsoListParagraph><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><a style='mso-comment-reference:KY_2;mso-comment-date:20131204T1610'><b
style='mso-bidi-font-weight:normal'>Special case</b></a><span
class=MsoCommentReference><b style='mso-bidi-font-weight:normal'><span
style='font-size:9.0pt;line-height:115%'><![if !supportAnnotations]><a
class=msocomanchor id="_anchor_2"
onmouseover="msoCommentShow('_anchor_2','_com_2')"
onmouseout="msoCommentHide('_com_2')" href="#_msocom_2" language=JavaScript
name="_msoanchor_2">[KY2]</a><![endif]><span style='mso-special-character:comment'>&nbsp;</span></span></b></span><b
style='mso-bidi-font-weight:normal'>:</b> If patient is already taking ARB, do
not stop prescription even if:</p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent SBP&lt;110 OR</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Creatinine &gt;=2.5 (male) OR creatinine&gt;=2.3
(female) OR</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=SpellE><span class=GramE>eGFR</span></span>
&lt;=30 (not yet encoded) OR</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Angioedema as a past recorded reaction to ACE inhibitor
(not yet encoded)</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoNormal>Note: while Pregnancy should be a strong contraindication,
there is no way to determine pregnancy from the data we have, so we will
instead issue a message to all women of childbearing age. </p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><a href="#ARBCompellingIndication">ARB Compelling Indication</a><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</p>

<p class=MsoNormal><span style='font-size:16.0pt;line-height:115%'><span
style="mso-spacerun:yes">&nbsp;</span><b style='mso-bidi-font-weight:normal'><u>Beta
Blockers (<span class=SpellE>carvedilol</span>, <span class=SpellE>metoprolol</span>
succinate, and <span class=SpellE>bisoprolol</span>)<o:p></o:p></u></b></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'>Guideline:</span></u>
</b>Use of 1 of the <b style='mso-bidi-font-weight:normal'>3 beta blockers</b>
proven to reduce mortality (i.e., <span class=SpellE>bisoprolol</span>, <span
class=SpellE>carvedilol</span>, and sustained-release <span class=SpellE>metoprolol</span>
succinate) is recommended for all patients with current or prior symptoms of <span
class=SpellE>HF<i>r</i>EF</span>, unless contraindicated, to reduce morbidity
and mortality (346, 416-419, 448). (<i>Level of Evidence: A</i>) &#8211; <span
class=SpellE>Yancy</span> 7.3.2.4 <span class=SpellE><span class=GramE>pg</span></span>
53</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Compelling indication
for <span class=SpellE>metoprolol</span> succinate or <span class=SpellE>bisoprolol</span>
or <span class=SpellE>carvedilol</span> <o:p></o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=40 AND</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Absence of MI AND</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Not already on any of the 3 recommended beta
blockers (note: if a patient is on a non-recommended beta blocker AND on a
recommended beta blocker, there will be NO recommendation to substitute the
non-recommended beta blocker)</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Compelling
indications for <span class=SpellE>carvedilol</span>: <o:p></o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=40 AND</p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence of MI AND</p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Not already on any of the three recommended beta
blockers (note: if a patient is on a non-recommended beta blocker AND on a
recommended beta blocker, there will be NO recommendation to substitute the
non-recommended beta blocker)</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Absolute
contraindications for <span class=SpellE>metoprolol</span> succinate, <span
class=SpellE>bisoprolol</span>, and <span class=SpellE>carvedilol</span><o:p></o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l20 level1 lfo14'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>None</p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Relative
contraindications for <span class=SpellE>metoprolol</span> succinate, <span
class=SpellE>bisoprolol</span>, and <span class=SpellE>carvedilol</span><o:p></o:p></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l20 level1 lfo14'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Aortic stenosis OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l20 level1 lfo14'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Hypotension (ICD9 code or most recent
SBP&lt;110) OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l20 level1 lfo14'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Asthma OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l20 level1 lfo14'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=SpellE>Bradycardia</span> (ICD9 code
or most recent pulse&lt;60) OR</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;mso-list:l20 level1 lfo14'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Prescription for verapamil OR <span
class=SpellE>diltiazem</span></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Special cases</b>:
patients with compelling indications for one of the three recommended <span
class=GramE>beta blockers</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l2 level1 lfo16'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=GramE>who</span> have an active
prescription for another beta blocker (except <span class=SpellE>sotalol</span>)
<span style='font-family:Wingdings;mso-ascii-font-family:Cambria;mso-ascii-theme-font:
minor-latin;mso-hansi-font-family:Cambria;mso-hansi-theme-font:minor-latin;
mso-char-type:symbol;mso-symbol-font-family:Wingdings'><span style='mso-char-type:
symbol;mso-symbol-font-family:Wingdings'></span></span> substitute for one of
the 3 recommended beta blockers for heart failure</p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l2 level1 lfo16'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=GramE>who</span> have an active
prescription for <span class=SpellE>sotalol</span> <span style='font-family:
Wingdings;mso-ascii-font-family:Cambria;mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;mso-hansi-theme-font:minor-latin;mso-char-type:
symbol;mso-symbol-font-family:Wingdings'><span style='mso-char-type:symbol;
mso-symbol-font-family:Wingdings'></span></span> no action</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
line-height:115%;font-family:Cambria;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Cambria;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span></b>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'>Aldosterone antagonists<o:p></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'>Guideline:</span></u>
Aldosterone receptor antagonists</b> [or mineralocorticoid receptor antagonists]
are recommended in patients with NYHA class II-IV and who have LVEF of 35% or
less, unless contraindicated, to reduce morbidity and mortality. Patients with
NYHA class II should have a history of prior cardiovascular hospitalization or
elevated plasma natriuretic peptide levels to be considered for aldosterone
receptor antagonists. Creatinine should be 2.5 mg/<span class=SpellE>dL</span>
or less in men or 2.0 mg/<span class=SpellE>dL</span> or less in women (or
estimated glomerular filtration rate &gt;30 mL/min/1.73 m2), and potassium
should be less than 5.0 <span class=SpellE>mEq</span>/L. Careful monitoring of
potassium, renal function, and diuretic dosing should be performed at
initiation and closely followed thereafter to minimize risk of hyperkalemia and
renal insufficiency (425, 426, 478). (Level of Evidence: A) <span class=SpellE>Yancy</span>
7.3.2.5 <span class=SpellE><span class=GramE>pg</span></span> 54</p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'>Aldosterone receptor antagonists</b> are recommended to reduce
morbidity and mortality following an acute MI in patients who have LVEF of 40%
or less who develop symptoms of HF or who have a history of diabetes mellitus,
unless contraindicates (446). (Level of Evidence: B) <span class=SpellE>Yancy</span>
7.3.2.5 <span class=SpellE><span class=GramE>pg</span></span> 54</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'>Compelling indications<o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-left:.25in'>Case #1: </p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=35 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(Creatinine &lt;2.5 (male) or creatinine&lt;2.0
(female) OR <span class=SpellE>eGFR</span>&gt;30) AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent K&lt;5 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence of ACE-I or ACE-I contraindicated or
ARB or ARB contraindicated AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(Presence of one of the three recommended BB (<span
class=SpellE>metoprolol</span> succinate, <span class=SpellE>bisoprolol</span>,
<span class=SpellE>carvedilol</span>) OR beta blocker contraindicated) AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Either</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(NYHA Class III/IV symptoms) OR </p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>((NYHA Class II symptoms AND Elevated BNP
defined as (BNP&gt;250)) or ((<span class=SpellE>NTproBNP</span>&gt;750 for
female or <span class=SpellE>NTproBNP</span>&gt;500 for male)) </p>

<p class=MsoNormal style='margin-left:.25in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'>Case #2:</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l13 level1 lfo18'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=40 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l13 level1 lfo18'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Most recent K&lt;5 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><a style='mso-comment-reference:
KY_4;mso-comment-date:20131209T1056'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(</a><a style='mso-comment-reference:KY_3;
mso-comment-date:20131209T1059'><span style='mso-comment-continuation:4'>MI
within last 6 months </span></a><span style='mso-comment-continuation:4'><span
class=MsoCommentReference><span style='font-size:9.0pt;line-height:115%'><![if !supportAnnotations]><a
class=msocomanchor id="_anchor_3"
onmouseover="msoCommentShow('_anchor_3','_com_3')"
onmouseout="msoCommentHide('_com_3')" href="#_msocom_3" language=JavaScript
name="_msoanchor_3">[KY3]</a><![endif]><span style='mso-special-character:comment'>&nbsp;</span></span></span>AND
NYHA Class II/ III/ IV symptoms) OR</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><span style='mso-comment-continuation:
4'><![if !supportLists]><span style='font-family:Calibri;mso-fareast-font-family:
Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(MI within last 6 months AND DM) </span><span
class=MsoCommentReference><span style='font-size:9.0pt;line-height:115%'><![if !supportAnnotations]><a
class=msocomanchor id="_anchor_4"
onmouseover="msoCommentShow('_anchor_4','_com_4')"
onmouseout="msoCommentHide('_com_4')" href="#_msocom_4" language=JavaScript
name="_msoanchor_4">[KY4]</a><![endif]><span style='mso-special-character:comment'>&nbsp;</span></span></span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:22.5pt'>Note:<span
style="mso-spacerun:yes">&nbsp; </span>If a patient is missing values for the
following variables, aldosterone antagonist recommendation will be suppressed: </p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class Symptoms </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Potassium </p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>BNP or <span class=SpellE>NTproBNP</span> (if
NYHA Class II symptoms. Otherwise, lack of BNP or <span class=SpellE>NTproBNP</span>
value will NOT suppress a recommendation)</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Absolute
Contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l16 level2 lfo20'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>CKD Stage 5 (ICD9 code) OR <span class=SpellE>eGFR</span>&lt;=30
OR creatinine &gt;=2.5 for men &gt;=2.0 for women (lowest wins) OR</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l16 level2 lfo20'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>AddisonÕs disease</p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Relative
Contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l16 level2 lfo20'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>CKD Stage 3 or 4 OR 30&lt;<span class=SpellE>eGFR</span>&lt;60
OR</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l16 level2 lfo20'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Potassium supplements OR</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l16 level2 lfo20'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Other potassium-sparing diuretics OR</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l16 level2 lfo20'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Non-steroidal anti-inflammatory drugs (NSAIDs)
OR</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l16 level2 lfo20'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Heparin OR</p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l16 level2 lfo20'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=SpellE>Cholestyramine</span></p>

<p class=MsoNormal style='margin-left:.5in'><o:p>&nbsp;</o:p></p>

<b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
line-height:115%;font-family:Cambria;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Cambria;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span></b>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'>Hydralazine<o:p></o:p></span></u></b></p>

<p class=MsoNormal>Note: should be given in combination with <span
class=SpellE>isosorbide</span> <span class=SpellE>dinitrates</span> (unless one
is contraindicated), but because they have different contraindications they are
listed separately. </p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'>Guideline:</span></u>
</b>The combination of <b style='mso-bidi-font-weight:normal'>hydralazine and <span
class=SpellE>isosorbide</span> <span class=SpellE>dinitrate</span></b> is
recommended to reduce morbidity and mortality for patients self-described as
African Americans with NYHA class III&#8211;IV <span class=SpellE>HFrEF</span>
receiving optimal therapy with ACE inhibitors and beta blockers, unless
contraindicated (423, 424). (Level of Evidence: A) <span class=SpellE>Yancy</span>
7.3.2.6 <span class=SpellE><span class=GramE>pg</span></span> 58</p>

<p class=MsoNormal style='margin-left:.25in'>A combination of <b
style='mso-bidi-font-weight:normal'>hydralazine and <span class=SpellE>isosorbide</span>
<span class=SpellE>dinitrate</span></b> can be useful to reduce morbidity or
mortality in patients with current or prior symptomatic <span class=SpellE>HF<i>r</i>EF</span>
who cannot be given an ACE inhibitor or ARB because of drug intolerance,
hypotension, or renal insufficiency, unless contraindicated (449). (Level of
Evidence: A)<span style='mso-fareast-font-family:"\FF2D\FF33 \660E\671D";
mso-fareast-theme-font:minor-fareast;color:black;mso-themecolor:text1;
mso-font-kerning:12.0pt'> </span><span class=SpellE>Yancy</span> 7.3.2.6 <span
class=SpellE><span class=GramE>pg</span></span> 58 (Class <span class=SpellE>IIa</span>)
</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Compelling
indications:<o:p></o:p></b></p>

<p class=MsoNormal style='margin-left:.25in'>Case #1:</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=40 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Self-identified African American AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class III or IV symptoms AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence of ACE-I or ACE-I contraindicated or
ARB or ARB contraindicated AND</p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence of one of the three recommended beta
blockers (<span class=SpellE>metoprolol</span> succinate, <span class=SpellE>bisoprolol</span>,
<span class=SpellE>carvedilol</span>) or beta blockers contraindicated </p>

<p class=MsoNormal style='margin-left:.25in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'>Case #2:</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=40 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class III or IV symptoms AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Absence of ACE or ARB and either</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(CDK Stage 4 or 5 or <span class=SpellE>eGFR</span>&lt;30)
OR</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>ADR to ACE or ADR to ARB </p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:22.5pt'>Note:<span
style="mso-spacerun:yes">&nbsp; </span>If a patient is missing values for the following
variables, hydralazine recommendation will be suppressed: </p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class Symptoms </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.0in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Race (for Case #1) </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto'><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><b
style='mso-bidi-font-weight:normal'>Absolute contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l11 level1 lfo22'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Lupus-like symptoms as an ADR to hydralazine OR</p>

<p class=MsoListParagraphCxSpMiddle><o:p>&nbsp;</o:p></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><b
style='mso-bidi-font-weight:normal'>Relative contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l3 level1 lfo24'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Lupus <span class=SpellE>Erythematosus</span>
Systemic </p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l12 level1 lfo26'><![if !supportLists]><span
style='font-size:12.0pt;line-height:115%;font-family:Calibri;mso-fareast-font-family:
Calibri;mso-bidi-font-family:Calibri'><span style='mso-list:Ignore'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
class=GramE>hypersensitivity</span> to hydralazine<b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'><o:p></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Special case:</b> If
most recent SBP &lt;110</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l12 level1 lfo26'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=GramE>and</span> patient NOT already
on hydralazine <span style='font-family:Wingdings;mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Cambria;mso-hansi-theme-font:
minor-latin;mso-char-type:symbol;mso-symbol-font-family:Wingdings'><span
style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'></span></span>
do not recommend to start </p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l12 level1 lfo26'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=GramE>and</span> patient IS already
on hydralazine <span style='font-family:Wingdings;mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Cambria;mso-hansi-theme-font:
minor-latin;mso-char-type:symbol;mso-symbol-font-family:Wingdings'><span
style='mso-char-type:symbol;mso-symbol-font-family:Wingdings'></span></span>
do not recommend to stop, but issue warning message that patient has
SBP&lt;110.</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><span class=SpellE><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'>Isosorbide</span></u></b></span><b
style='mso-bidi-font-weight:normal'><u><span style='font-size:16.0pt;
line-height:115%'> <span class=SpellE>dinitrates</span></span></u></b><b
style='mso-bidi-font-weight:normal'><span style='font-size:16.0pt;line-height:
115%'> </span></b><span style='font-size:16.0pt;line-height:115%'><o:p></o:p></span></p>

<p class=MsoNormal>Note: should be given in combination with hydralazine
(unless one is contraindicated), but because they have different
contraindications they are listed separately. </p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'>Guideline:</span></u>
</b>The combination of <b style='mso-bidi-font-weight:normal'>hydralazine and <span
class=SpellE>isosorbide</span> <span class=SpellE>dinitrate</span></b> is
recommended to reduce morbidity and mortality for patients self-described as
African Americans with NYHA class III&#8211;IV <span class=SpellE>HFrEF</span>
receiving optimal therapy with ACE inhibitors and beta blockers, unless
contraindicated (423, 424). (Level of Evidence: A) <span class=SpellE>Yancy</span>
7.3.2.6 <span class=SpellE><span class=GramE>pg</span></span> 58</p>

<p class=MsoNormal style='margin-left:.25in'>A combination of <b
style='mso-bidi-font-weight:normal'>hydralazine and <span class=SpellE>isosorbide</span>
<span class=SpellE>dinitrate</span></b> can be useful to reduce morbidity or
mortality in patients with current or prior symptomatic <span class=SpellE>HF<i>r</i>EF</span>
who cannot be given an ACE inhibitor or ARB because of drug intolerance,
hypotension, or renal insufficiency, unless contraindicated (449). (Level of
Evidence: A)<span style='mso-fareast-font-family:"\FF2D\FF33 \660E\671D";
mso-fareast-theme-font:minor-fareast;color:black;mso-themecolor:text1;
mso-font-kerning:12.0pt'> </span><span class=SpellE>Yancy</span> 7.3.2.6 <span
class=SpellE><span class=GramE>pg</span></span> 58 (Class <span class=SpellE>IIa</span>)
</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Compelling
indications<o:p></o:p></b></p>

<p class=MsoNormal style='margin-left:.25in'>Case #1:</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=40 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Self-identified African American AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class III or IV symptoms AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence of ACE-I or ACE-I contraindicated or
ARB or ARB contraindicated AND</p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence of one of the three recommended BB (<span
class=SpellE>metoprolol</span> succinate, <span class=SpellE>bisoprolol</span>,
<span class=SpellE>carvedilol</span>) OR beta blocker contraindicated </p>

<p class=MsoNormal style='margin-left:.25in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'>Case #2 </p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=40 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYA Class III or IV symptoms AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Absence of ACE or ARB and either</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(CDK Stage 4 or 5 or <span class=SpellE>eGFR</span>&lt;30)
or</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>ADR to ACE or ADR to ARB </p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:22.5pt'>Note:<span
style="mso-spacerun:yes">&nbsp; </span>If a patient is missing values for the
following variables, <span class=SpellE>isosorbide</span> <span class=SpellE>dinitrate</span>
recommendation will be suppressed: </p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class Symptoms </p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Race (for Case #1)</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;mso-add-space:auto'><b
style='mso-bidi-font-weight:normal'>Absolute contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:l19 level1 lfo28'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Active prescription for <span class=SpellE>phosphodiesterase</span>
inhibitors (sildenafil, <span class=SpellE>vardenafil</span>, or <span
class=SpellE>tadalafil</span>) </p>

<p class=MsoListParagraphCxSpMiddle><o:p>&nbsp;</o:p></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;mso-add-space:auto'><b
style='mso-bidi-font-weight:normal'>Relative contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l5 level2 lfo30'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Hypersensitivity to nitrates</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Special case:</b> If
most recent SBP &lt;110</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l12 level1 lfo26'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=GramE>and</span> patient NOT already
on <span class=SpellE>isosorbide</span> <span class=SpellE>dinitrate</span> <span
style='font-family:Wingdings;mso-ascii-font-family:Cambria;mso-ascii-theme-font:
minor-latin;mso-hansi-font-family:Cambria;mso-hansi-theme-font:minor-latin;
mso-char-type:symbol;mso-symbol-font-family:Wingdings'><span style='mso-char-type:
symbol;mso-symbol-font-family:Wingdings'></span></span> do not recommend to
start </p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l12 level1 lfo26'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span class=GramE>and</span> patient IS already
on <span class=SpellE>isosorbide</span> <span class=SpellE>dinitrate</span> <span
style='font-family:Wingdings;mso-ascii-font-family:Cambria;mso-ascii-theme-font:
minor-latin;mso-hansi-font-family:Cambria;mso-hansi-theme-font:minor-latin;
mso-char-type:symbol;mso-symbol-font-family:Wingdings'><span style='mso-char-type:
symbol;mso-symbol-font-family:Wingdings'></span></span> do not recommend to
stop, but issue warning message that patient has SBP&lt;110.</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
line-height:115%;font-family:Cambria;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Cambria;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
</span></b>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'>Implantable <span class=SpellE>Cardioverter-Debibrillator</span>
(ICD)<o:p></o:p></span></u></b></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'>Guideline:</span></u>
ICD therapy</b> is recommended for primary prevention of SCD to reduce total
mortality in selected patients with <span class=SpellE>nonischemic</span> DCM
or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and
NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation
of meaningful survival for more than 1 year (355, 593). (Level of
Evidence:<span style="mso-spacerun:yes">&nbsp; </span>A) <span class=SpellE>Yancy</span>
7.3.4 <span class=SpellE><span class=GramE>pg</span></span> 70</p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'>ICD therapy</b> is recommended for primary prevention of SCD to reduce
total mortality in selected patients at least 40 days post-MI with LVEF of30%
or less, and NYHA class I symptoms while receiving GDMT, who have reasonable
expectation of meaningful survival for more than 1 year (362, 597, 598). (Level
of Evidence:<span style="mso-spacerun:yes">&nbsp; </span>B) <span class=SpellE>Yancy</span>
7.3.4 <span class=SpellE><span class=GramE>pg</span></span> 70</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>*Note: See Appendix for our definition of Guideline-Directed
Medical Therapy (GDMT)</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Compelling
indications<o:p></o:p></b></p>

<p class=MsoNormal style='margin-left:.25in'>Case #1:</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF&lt;=35 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class II or III symptoms AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence of MI at least 40 days old (cannot
encode non-ischemic dilated cardiomyopathy) AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Guideline Directed Medical Therapy: </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>ACE-I or ARB or contraindications to ACE or ARB
AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>BB or contraindications to BB AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>Aldosterone antagonist or contraindications to
aldosterone antagonist AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>Either</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level2 lfo32'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>((African
American and Hydralazine and nitrates or contraindicated to either) OR</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level2 lfo32'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Absence
of ACE or ARB and either</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:2.0in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>(CDK Stage 4 or 5 or <span class=SpellE>eGFR</span>&lt;30)
or ADR to ACE or ADR to ARB</p>

<p class=MsoListParagraphCxSpLast style='margin-left:2.0in;mso-add-space:auto'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'>Case #2:</p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l14 level1 lfo34'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF &lt;=30 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class I AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Presence of MI at least 40 days old AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Guideline Directed Medical Therapy: </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>ACE-I or ARB or contraindications to ACE or ARB
AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>BB or contraindications to BB AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>Aldosterone antagonist or contraindications to
aldosterone antagonist AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>Either</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level2 lfo32'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
style="mso-spacerun:yes">&nbsp;</span>((African American and Hydralazine and
nitrates or contraindicated to either) OR</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level2 lfo32'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>Absence
of ACE or ARB and either</p>

<p class=MsoListParagraphCxSpLast style='margin-left:1.25in;mso-add-space:auto'>(CDK
Stage 4 or 5 or <span class=SpellE>eGFR</span>&lt;30) or ADR to ACE or ADR to
ARB <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></p>

<b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
line-height:115%;font-family:Cambria;mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Cambria;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:
minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-left:22.5pt'>Note:<span
style="mso-spacerun:yes">&nbsp; </span>If a patient is missing values for the
following variables, implantable <span class=SpellE>cardioverter</span>-defibrillator
recommendation will be suppressed: </p>

<p class=MsoListParagraph style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class Symptoms </p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;mso-add-space:auto'><b
style='mso-bidi-font-weight:normal'>Absolute contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l19 level1 lfo28'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Palliative care</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:12.0pt;line-height:115%'><o:p><span style='text-decoration:
 none'>&nbsp;</span></o:p></span></u></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><u><span
style='font-size:16.0pt;line-height:115%'>Cardiac Resynchronization Therapy
(CRT)<o:p></o:p></span></u></b></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'><b style='mso-bidi-font-weight:
normal'><u><span style='font-size:12.0pt;line-height:115%'>Guideline:</span></u>
CRT</b> is indicated for patients who have LVEF of 35% or less, sinus rhythm,
left bundle-branch block (LBBB) with a QRS duration of 150 <span class=SpellE>ms</span>
or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. <i>(Level
of Evidence: A for NYHA class III/IV </i>(38, 78, 116, 594); <i>Level of</i> <i>Evidence:
B for NYHA class II </i>(595, 596)) <span class=SpellE>Yancy</span> 7.3.4 <span
class=SpellE><span class=GramE>pg</span></span> 70</p>

<p class=MsoNormal style='margin-left:.25in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>*Note: See Appendix for our definition of Guideline-Directed
Medical Therapy (GDMT)</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>Compelling indication<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>LVEF &lt;=35 AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class II or III or IV <a style='mso-comment-reference:
OCM_5;mso-comment-date:20131204T1610'>ambulatory </a><span
class=MsoCommentReference><span style='font-size:9.0pt;line-height:115%'><![if !supportAnnotations]><a
class=msocomanchor id="_anchor_5"
onmouseover="msoCommentShow('_anchor_5','_com_5')"
onmouseout="msoCommentHide('_com_5')" href="#_msocom_5" language=JavaScript
name="_msoanchor_5">[OCM5]</a><![endif]><span style='mso-special-character:
comment'>&nbsp;</span></span></span>symptoms AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l10 level1 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Guideline Directed Medical Therapy: </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>ACE-I or ARB or contraindications to ACE or ARB
AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>BB or contraindications to BB AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>Aldosterone antagonist or contraindications to
aldosterone antagonist AND</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level1 lfo32'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>Either</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:2.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l4 level2 lfo32'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
style="mso-spacerun:yes">&nbsp;</span>(African American and Hydralazine and
(nitrates or contraindicated to either)) OR</p>

<p class=MsoListParagraphCxSpLast style='margin-left:2.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l4 level2 lfo32'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>((Absence
of ACE or ARB) and (CDK Stage 4 or 5 or <span class=SpellE>eGFR</span>&lt;30 or
ADR to ACE or ADR to ARB)) </p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:22.5pt'>Note:<span
style="mso-spacerun:yes">&nbsp; </span>If a patient is missing values for the
following variables, cardiac resynchronization therapy recommendation will be
suppressed: </p>

<p class=MsoListParagraph style='margin-left:1.0in;mso-add-space:auto;
text-indent:-.25in;mso-list:l10 level2 lfo12'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>NYHA Class Symptoms </p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;mso-add-space:auto'><b
style='mso-bidi-font-weight:normal'>Absolute contraindications<o:p></o:p></b></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l19 level1 lfo28'><![if !supportLists]><span
style='font-family:Calibri;mso-fareast-font-family:Calibri;mso-bidi-font-family:
Calibri'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Palliative care</p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p></b></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;line-height:115%'>Primary messages selected for
testing: <o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:16.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;mso-add-space:auto;
text-indent:-.25in;mso-list:l0 level1 lfo36'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>Combined
use of ACE, ARB, and aldosterone antagonist</b>:<span style='color:black'>
ÒRoutine combined use of an ACEI, ARB, and aldosterone antagonist is NOT
RECOMMENDED for patients with current or prior symptoms of HF and reduced LVEF.
(Level of Evidence: C)Ó</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level2 lfo36'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>This
message is triggered when a patient is on all three drugs. </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto'><o:p>&nbsp;</o:p></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level1 lfo36'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>Patient
is taking drugs harmful to HF: Ò</b><span style='color:black'>Drugs known to
adversely affect the clinical status of patients with current or prior symptoms
of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., <span
class=SpellE>nonsteroidal</span> anti-inflammatory drugs (not aspirin), most
antiarrhythmic drugs, most calcium channel blocking drugs (except amlodipine)
and <span class=SpellE>thiazolidinediones</span>). (Level of Evidence: B)Ó</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.75in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level2 lfo36'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>This
message is triggered if a patient is on one of these harmful drugs: </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level3 lfo36'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>Calcium-channel blockers with negative inotropic
effects (<span class=SpellE>nifedipine</span>, <span class=SpellE>nisoldipine</span>,
<span class=SpellE>nicardipine</span>, <span class=SpellE>isradipine</span>, <span
class=SpellE>diltiazem</span>, verapamil) </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level3 lfo36'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span class=SpellE>Thiazolidinediones</span>
(rosiglitazone, pioglitazone) </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level3 lfo36'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]>Non-steroidal anti-inflammatory drugs (<span
class=SpellE>Aceclofenac</span>, <span class=SpellE>acemetacin</span>, <span
class=SpellE>azapropazone</span>, <span class=SpellE>benoxaprofen</span>, <span
class=SpellE>bromfenac</span>, ibuprofen) </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level3 lfo36'><![if !supportLists]><span
style='font-family:Wingdings;mso-fareast-font-family:Wingdings;mso-bidi-font-family:
Wingdings'><span style='mso-list:Ignore'>¤<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span></span><![endif]><span class=SpellE>Dronedarone</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:1.25in;mso-add-space:
auto'><o:p>&nbsp;</o:p></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;mso-add-space:
auto;text-indent:-.25in;mso-list:l0 level1 lfo36'><![if !supportLists]><span
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'>á<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>Woman of <span
class=GramE>child-bearing</span> age: </b>Ò(message text has not yet been
decided or encodedÉ but it will warn that women of childbearing age should not
be on certain drugs (ACE, ARBÉ))Ó</p>

<p class=MsoListParagraphCxSpLast style='margin-left:.75in;mso-add-space:auto;
text-indent:-.25in;mso-list:l0 level2 lfo36'><![if !supportLists]><span
style='font-family:"Courier New";mso-fareast-font-family:"Courier New";
mso-bidi-font-family:"Courier New"'><span style='mso-list:Ignore'>o<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]>This
message will be triggered if a woman is age &lt;=50.</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'>APPENDIX A: ICD9 Codes <o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'>Heart Failure: <o:p></o:p></span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=370
 style='width:370.2pt;margin-left:4.65pt;border-collapse:collapse;mso-yfti-tbllook:
 1184;mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><b><span style='font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>ICD9 code<o:p></o:p></span></b></p>
  </td>
  <td width=311 nowrap valign=bottom style='width:311.2pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-top-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><b><span style='font-family:
  Calibri;mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Description<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>402.11<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Benign with Heart Failure<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>402.91<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Unspecified with Heart Failure<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;background:
  yellow;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  background:yellow;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Heart Failure<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;background:
  yellow;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  background:yellow;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Congestive heart failure, unspecified<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:5;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.1<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Left heart failure<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:6;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.9<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Heart failure, unspecified<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:7;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>429.3<o:p></o:p></span></p>
  </td>
  <td width=311 nowrap valign=bottom style='width:311.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Cardiomegaly<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:8;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>425.0<o:p></o:p></span></p>
  </td>
  <td width=311 nowrap valign=bottom style='width:311.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Cardiomyopathy<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:9;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>425.3<o:p></o:p></span></p>
  </td>
  <td width=311 nowrap valign=bottom style='width:311.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span class=SpellE><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'>Endocardial</span></span><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'> <span class=SpellE>fibroelastosis</span><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:10;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>425.4<o:p></o:p></span></p>
  </td>
  <td width=311 nowrap valign=bottom style='width:311.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Other primary cardiomyopathies <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:11;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>425.5<o:p></o:p></span></p>
  </td>
  <td width=311 nowrap valign=bottom style='width:311.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Alcoholic Cardiomyopathy <o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:12;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>425.8<o:p></o:p></span></p>
  </td>
  <td width=311 nowrap valign=bottom style='width:311.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>CARDIOMYOPATHY IN OTHER DISEASES CLASSIFIED ELSEWHERE<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:13;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>425.9<o:p></o:p></span></p>
  </td>
  <td width=311 nowrap valign=bottom style='width:311.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>SECONDARY CARDIOMYOPATHY UNSPECIFIED<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:14;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>402<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Hypertensive Heart Disease<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:15;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>402.01<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Malignant with Heart Failure<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:16;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>404<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Hypertensive heart and Chronic Kidney Disease<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:17;height:30.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>404.01<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Malignant, with HF and with CKD stage I through IV or
  unspecified<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:18;height:30.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>404.03<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Malignant, with HF and CKD stage V or end stage renal disease<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:19;height:30.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>404.11<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Benign, with HF and with CKD stage I through IV or unspecified<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:20;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>404.13<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Benign, with HF and CKD stage V or end stage renal disease<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:21;height:30.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>404.91<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Unspecified, with HF and CKD stage I through IV or unspecified<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:22;height:30.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>404.93<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Unspecified, with HF and CKD stage V or end stage renal disease<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:23;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.2<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Systolic heart failure, Unspecified<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:24;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.21<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Systolic heart failure, acute<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:25;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.22<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Systolic heart failure, chronic<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:26;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.23<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Systolic heart failure, acute on chronic<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:27;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.3<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Diastolic heart failure, unspecified<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:28;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.31<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Diastolic heart failure, Acute<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:29;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.32<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Diastolic heart failure, chronic<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:30;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.33<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Diastolic heart failure, acute on chronic<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:31;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.4<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Combined systolic and diastolic heart failure, unspecified<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:32;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.41<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Combined systolic and diastolic heart failure, acute<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:33;height:15.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.42<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Combined systolic and diastolic heart failure, chronic<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:34;mso-yfti-lastrow:yes;height:30.0pt'>
  <td width=59 nowrap valign=bottom style='width:59.0pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>428.43<o:p></o:p></span></p>
  </td>
  <td width=311 valign=bottom style='width:311.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.0pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>Combined systolic and diastolic heart failure, acute on chronic<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'>Heart Transplant:<o:p></o:p></span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=357
 style='width:356.95pt;margin-left:4.65pt;border-collapse:collapse;mso-yfti-tbllook:
 1184;mso-padding-alt:0in 5.4pt 0in 5.4pt'>
 <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;height:16.1pt'>
  <td width=36 nowrap valign=bottom style='width:35.85pt;border:solid windowtext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal style='line-height:normal'><span class=SpellE><b><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'>ICDCode</span></b></span><b><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'><o:p></o:p></span></b></p>
  </td>
  <td width=321 nowrap valign=bottom style='width:321.1pt;border:solid windowtext 1.0pt;
  border-left:none;mso-border-top-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal style='line-height:normal'><span class=SpellE><b><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'>ICDDescription</span></b></span><b><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'><o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:1;height:16.1pt'>
  <td width=36 nowrap valign=bottom style='width:35.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>V42.1<o:p></o:p></span></p>
  </td>
  <td width=321 nowrap valign=bottom style='width:321.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>HEART REPLACED BY TRANSPLANT<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:2;height:16.1pt'>
  <td width=36 nowrap valign=bottom style='width:35.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'>996.83<o:p></o:p></span></p>
  </td>
  <td width=321 nowrap valign=bottom style='width:321.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>COMPLICATIONS OF TRANSPLANTED HEART<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:3;height:16.1pt'>
  <td width=36 nowrap valign=bottom style='width:35.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'>414.06<o:p></o:p></span></p>
  </td>
  <td width=321 nowrap valign=bottom style='width:321.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>CORONARY ATHEROSCLEROSIS, OF NATIVE CORONARY ARTERY OF
  TRANSPLANTED HEART<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-yfti-irow:4;mso-yfti-lastrow:yes;height:16.1pt'>
  <td width=36 nowrap valign=bottom style='width:35.85pt;border:solid windowtext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bottom-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal align=right style='text-align:right;line-height:normal'><span
  style='font-family:Calibri;mso-fareast-font-family:"Times New Roman";
  mso-bidi-font-family:"Times New Roman";color:black'>414.07<o:p></o:p></span></p>
  </td>
  <td width=321 nowrap valign=bottom style='width:321.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  mso-border-bottom-alt:solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.1pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:Calibri;
  mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
  color:black'>CORONARY ATHEROSCLEROSIS, OF BYPASS GRAFT (ARTERY) (VEIN) OF
  TRANSPLANTED HEART<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'>APPENDIX B: Recommendations extracted
from Circulation, <span class=SpellE>Yancy</span>, et al 2013<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;line-height:115%'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><u><span style='font-size:12.0pt;line-height:115%'>ACE
inhibitors<o:p></o:p></span></u></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l17 level1 lfo38;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>ACE
inhibitors</b> are recommended in patients with <span class=SpellE>HF<i>r</i>EF</span>
and current or prior symptoms, unless contraindicated, to reduce morbidity and
mortality (343, 412-414). (<i>Level of Evidence: A</i>) &#8211; <span
class=SpellE>Yancy</span> 7.3.2.2 <span class=SpellE>pg</span> 49</p>

<p class=MsoNormal style='margin-left:.5in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><u>Angiotensin receptor blockers<o:p></o:p></u></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l17 level1 lfo38;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>ARBs </b>are
recommended in patients with <span class=SpellE>HFrEF</span> with current or
prior symptoms<b><i> </i></b>who are ACE inhibitor intolerant, unless
contraindicated, to reduce morbidity and mortality<span
style="mso-spacerun:yes">&nbsp; </span>(108, 345, 415, 450). (<i>Level of <span
class=SpellE>Evidence<span class=GramE>:A</span></span></i>) &#8211; <span
class=SpellE>Yancy</span> 7.3.2.3 <span class=SpellE>pg</span> 51</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><span class=GramE><u>Beta blockers</u></span><u><o:p></o:p></u></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l17 level1 lfo38;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Use of 1 of the <b style='mso-bidi-font-weight:
normal'>3 beta blockers</b> proven to reduce mortality (i.e., <span
class=SpellE>bisoprolol</span>, <span class=SpellE>carvedilol</span>, and
sustained-release <span class=SpellE>metoprolol</span> succinate) is
recommended for all patients with current or prior symptoms of <span
class=SpellE>HF<i>r</i>EF</span>, unless contraindicated, to reduce morbidity
and mortality (346, 416-419, 448). (<i>Level of Evidence: A</i>) &#8211; <span
class=SpellE>Yancy</span> 7.3.2.4 <span class=SpellE>pg</span> 53</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><u>Aldosterone antagonists<o:p></o:p></u></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l17 level1 lfo38;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>Aldosterone
receptor antagonists</b> [or mineralocorticoid receptor antagonists] are
recommended in patients with NYHA class II-IV and who have LVEF of 35% or less,
unless contraindicated, to reduce morbidity and mortality. Patients with NYHA
class II should have a history of prior cardiovascular hospitalization or
elevated plasma natriuretic peptide levels to be considered for aldosterone
receptor antagonists. Creatinine should be 2.5 mg/<span class=SpellE>dL</span>
or less in men or 2.0 mg/<span class=SpellE>dL</span> or less in women (or
estimated glomerular filtration rate &gt;30 mL/min/1.73 m2), and potassium
should be less than 5.0 <span class=SpellE>mEq</span>/L. Careful monitoring of
potassium, renal function, and diuretic dosing should be performed at
initiation and closely followed thereafter to minimize risk of hyperkalemia and
renal insufficiency (425, 426, 478). (Level of Evidence: A) <span class=SpellE>Yancy</span>
7.3.2.5 <span class=SpellE>pg</span> 54</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l17 level1 lfo38;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>Aldosterone
receptor antagonists</b> are recommended to reduce morbidity and mortality
following an acute MI in patients who have LVEF of 40% or less who develop
symptoms of HF or who have a history of diabetes mellitus, unless
contraindicates (446). (Level of Evidence: B) <span class=SpellE>Yancy</span>
7.3.2.5 <span class=SpellE>pg</span> 54</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><u>Hydralazine and nitrates</u></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l7 level1 lfo40;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>The combination of <b style='mso-bidi-font-weight:
normal'>hydralazine and <span class=SpellE>isosorbide</span> <span
class=SpellE>dinitrate</span></b> is recommended to reduce morbidity and
mortality for patients self-described as African Americans with NYHA class
III&#8211;IV <span class=SpellE>HFrEF</span> receiving optimal therapy with ACE
inhibitors and beta blockers, unless contraindicated (423, 424). (Level of
Evidence: A) <span class=SpellE>Yancy</span> 7.3.2.6 <span class=SpellE>pg</span>
58</p>

<p class=MsoNormal style='margin-left:.25in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l7 level1 lfo40;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>A combination of <b style='mso-bidi-font-weight:
normal'>hydralazine and <span class=SpellE>isosorbide</span> <span
class=SpellE>dinitrate</span></b> can be useful to reduce morbidity or
mortality in patients with current or prior symptomatic <span class=SpellE>HF<i>r</i>EF</span>
who cannot be given an ACE inhibitor or ARB because of drug intolerance,
hypotension, or renal insufficiency, unless contraindicated (449). (Level of
Evidence: A)<span style='mso-fareast-font-family:"\FF2D\FF33 \660E\671D";
mso-fareast-theme-font:minor-fareast;color:black;mso-themecolor:text1;
mso-font-kerning:12.0pt'> </span><span class=SpellE>Yancy</span> 7.3.2.6 <span
class=SpellE>pg</span> 58 (Class <span class=SpellE>IIa</span>) </p>

<p class=MsoNormal style='margin-left:.5in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'><u>Implantable <span class=SpellE>cardioverter</span>
defibrillator<o:p></o:p></u></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l7 level1 lfo40;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>ICD
therapy</b> is recommended for primary prevention of SCD to reduce total
mortality in selected patients with <span class=SpellE>nonischemic</span> DCM
or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and
NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation
of meaningful survival for more than 1 year (355, 593). (Level of
Evidence:<span style="mso-spacerun:yes">&nbsp; </span>A) <span class=SpellE>Yancy</span>
7.3.4 <span class=SpellE>pg</span> 70</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l7 level1 lfo40;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>ICD
therapy</b> is recommended for primary prevention of SCD to reduce total
mortality in selected patients at least 40 days post-MI with LVEF of30% or
less, and NYHA class I symptoms while receiving GDMT, who have reasonable
expectation of meaningful survival for more than 1 year (362, 597, 598). (Level
of Evidence:<span style="mso-spacerun:yes">&nbsp; </span>B) <span class=SpellE>Yancy</span>
7.3.4 <span class=SpellE>pg</span> 70</p>

<p class=MsoNormal style='margin-left:.5in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'><u>Cardiac resynchronization
therapy<o:p></o:p></u></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l7 level1 lfo40;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style='mso-bidi-font-weight:normal'>CRT</b>
is indicated for patients who have LVEF of 35% or less, sinus rhythm, left
bundle-branch block (LBBB) with a QRS duration of 150 <span class=SpellE>ms</span>
or greater, and NYHA class II, III, or ambulatory IV symptoms on GDMT. <i>(Level
of Evidence: A for NYHA class III/IV </i>(38, 78, 116, 594); <i>Level of</i> <i>Evidence:
B for NYHA class II </i>(595, 596)) <span class=SpellE>Yancy</span> 7.3.4 <span
class=SpellE>pg</span> 70</p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in'><u>Other<o:p></o:p></u></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l9 level1 lfo42;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Routine <i>combined </i>use of an ACE inhibitor,
ARB, and aldosterone antagonist is potentially harmful for patients with <span
class=SpellE>HF<i>r</i>EF</span>. (<i>Level of Evidence: C</i>) <span
class=SpellE>Yancy</span> 7.3.2.3, <span class=SpellE>pg</span> 51</p>

<p class=MsoNormal style='margin-left:.25in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;mso-list:l9 level1 lfo42;
tab-stops:list .25in'><![if !supportLists]><span style='font-family:Arial;
mso-fareast-font-family:Arial;mso-bidi-font-family:Arial'><span
style='mso-list:Ignore'>¥<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]>Drugs known to adversely affect the clinical
status of patients with current or prior symptoms of <span class=SpellE>HF<i>r</i>EF</span>
are potentially harmful and should be avoided or withdrawn whenever possible
(e.g., most antiarrhythmic drugs, most calcium channel blocking drugs (except
amlodipine), NSAIDs, or <span class=SpellE>thiazolidinediones</span>)
(546-557). <i>(Level of Evidence: B) <span class=SpellE>Yancy</span> 7.3.2.9</i></p>

<p class=MsoNormal style='margin-left:.5in'><o:p>&nbsp;</o:p></p>

<p class=MsoNormal style='page-break-after:avoid'><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><o:p>&nbsp;</o:p></p>

<p class=MsoCaption><span style='font-size:16.0pt;color:windowtext'>Figure </span><!--[if supportFields]><span
style='font-size:16.0pt;color:windowtext'><span style='mso-element:field-begin'></span><span
style="mso-spacerun:yes">&nbsp;</span>SEQ Figure \* ARABIC <span
style='mso-element:field-separator'></span></span><![endif]--><span
style='font-size:16.0pt;color:windowtext'><span style='mso-no-proof:yes'>1</span></span><!--[if supportFields]><span
style='font-size:16.0pt;color:windowtext;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span><![endif]--><span style='font-size:
16.0pt;color:windowtext'> Guideline-directed medical therapy (GDMT) from <span
class=SpellE>Yancy</span> et al. 2013<o:p></o:p></span></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'>NOTE: </b>Diuretic therapy
is beyond the scope of this project. Therefore, this project uses an adaptation
of the GDMT chart above. This projectÕs version of GDMT assumes that diuretics
are prescribed if indicated, and that diuretics are absent when not indicated. </p>

</div>

<div style='mso-element:comment-list'><![if !supportAnnotations]>

<hr class=msocomoff align=left size=1 width="33%">

<![endif]>

<div style='mso-element:comment'><![if !supportAnnotations]>

<div id="_com_1" class=msocomtxt language=JavaScript
onmouseover="msoCommentShow('_anchor_1','_com_1')"
onmouseout="msoCommentHide('_com_1')"><![endif]><span style='mso-comment-author:
"Samson Tu"'><![if !supportAnnotations]><a name="_msocom_1"></a><![endif]></span>

<p class=MsoCommentText><span class=MsoCommentReference><span style='font-size:
9.0pt'><span style='mso-special-character:comment'>&nbsp;<![if !supportAnnotations]><a
href="#_msoanchor_1" class=msocomoff>[ST1]</a><![endif]></span></span></span>This
is a test</p>

<![if !supportAnnotations]></div>

<![endif]></div>

<div style='mso-element:comment'><![if !supportAnnotations]>

<div id="_com_2" class=msocomtxt language=JavaScript
onmouseover="msoCommentShow('_anchor_2','_com_2')"
onmouseout="msoCommentHide('_com_2')"><![endif]><span style='mso-comment-author:
vhapalyuenk'><![if !supportAnnotations]><a name="_msocom_2"></a><![endif]></span>

<p class=MsoCommentText><span class=MsoCommentReference><span style='font-size:
9.0pt'><span style='mso-special-character:comment'>&nbsp;<![if !supportAnnotations]><a
href="#_msoanchor_2" class=msocomoff>[KY2]</a><![endif]></span></span></span>Double
check if this should really be the same as ACE &#8211; I think that Paul might
have said something different for ACE and ARB special cases</p>

<![if !supportAnnotations]></div>

<![endif]></div>

<div style='mso-element:comment'><![if !supportAnnotations]>

<div id="_com_3" class=msocomtxt language=JavaScript
onmouseover="msoCommentShow('_anchor_3','_com_3')"
onmouseout="msoCommentHide('_com_3')"><![endif]><span style='mso-comment-author:
vhapalyuenk'><![if !supportAnnotations]><a name="_msocom_3"></a><![endif]></span>

<p class=MsoCommentText><span class=MsoCommentReference><span style='font-size:
9.0pt'><span style='mso-special-character:comment'>&nbsp;<![if !supportAnnotations]><a
href="#_msoanchor_3" class=msocomoff>[KY3]</a><![endif]></span></span></span>Clarify
temporal relationship between MI and HF ICD9 code. Should Òdevelop symptoms of
HFÓ be operationalized as ICD9 code for HF? Or presence of NYHA Class II<span
class=GramE>,III,IV</span> symptoms? Are these patients that developed HF after
MI? So patients with recently developed HF? Or are these patients that already
have HF and have MI and have worsening of symptoms? Both? These are Stage C recommendations.
</p>

<![if !supportAnnotations]></div>

<![endif]></div>

<div style='mso-element:comment'><![if !supportAnnotations]>

<div id="_com_4" class=msocomtxt language=JavaScript
onmouseover="msoCommentShow('_anchor_4','_com_4')"
onmouseout="msoCommentHide('_com_4')"><![endif]><span style='mso-comment-author:
vhapalyuenk'><![if !supportAnnotations]><a name="_msocom_4"></a><![endif]></span>

<p class=MsoCommentText><span class=MsoCommentReference><span style='font-size:
9.0pt'><span style='mso-special-character:comment'>&nbsp;<![if !supportAnnotations]><a
href="#_msoanchor_4" class=msocomoff>[KY4]</a><![endif]></span></span></span>Ask
Mary/Paul/Mike about their interpretations of the guideline </p>

<![if !supportAnnotations]></div>

<![endif]></div>

<div style='mso-element:comment'><![if !supportAnnotations]>

<div id="_com_5" class=msocomtxt language=JavaScript
onmouseover="msoCommentShow('_anchor_5','_com_5')"
onmouseout="msoCommentHide('_com_5')"><![endif]><span style='mso-comment-author:
"Oshiro\, Connie M\."'><![if !supportAnnotations]><a name="_msocom_5"></a><![endif]></span>

<p class=MsoCommentText><span class=MsoCommentReference><span style='font-size:
9.0pt'><span style='mso-special-character:comment'>&nbsp;<![if !supportAnnotations]><a
href="#_msoanchor_5" class=msocomoff>[OCM5]</a><![endif]></span></span></span>PH
question:<span style="mso-spacerun:yes">&nbsp; </span>why ambulatory?</p>

<![if !supportAnnotations]></div>

<![endif]></div>

</div>

</body>

</html>
